Compare Citius Pharmaceuticals Inc (CTXR) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Zoom Video Communications, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Zoom Video Communications, Inc. trades at $93.45 (market cap $26.73B). The key difference: Zoom Video Communications, Inc. is far larger — about 1825.8× Citius Pharmaceuticals Inc's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | ZM | |
|---|---|---|
Market Cap | $14.64M | $26.73B |
Sector | Health | Technology |
52-Week High | $1.82 | $111.88 |
52-Week Low | $0.53 | $69.77 |
Enterprise Value | $10.86M | $19.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Zoom Communications (ZM) trades at $91.88, up 2.36% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong profitability with a net income margin of 41.99% and a P/E ratio of 13.53, trading below the analyst consensus price target of $118.79. Recent developments include the acquisition of Common Room and expansion of AI-powered Zoom Virtual Agent capabilities, signaling growth initiatives.
The outlook for ZM is positive, supported by robust cash flow, AI integration, and an undervalued stake in Anthropic ahead of its IPO. Risks include competitive pressure from Microsoft and Google, insider selling, and fluctuating cash flow trends. Wall Street sentiment is mixed, with 39% of analysts rating it a buy, but the stock offers value if execution on AI-driven growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
